Mechanism of 
action

SPEVIGO® is the only IL-36 inhibitor indicated in the treatment of GPP flares¹*

There is evidence that suggests that there is a link between IL-36 receptor (IL-36R) signalling and skin inflammation¹*

• The precise mechanism of how the decrease in IL-36R signalling in the skin of GPP patients is linked to treatment is not clear

SPEVIGO® is a humanized antagonistic monoclonal IgG1 antibody that blocks IL-36R signalling¹*

• Binding to IL-36R prevents the subsequent activation of IL-36R by cognate ligands (IL-36α, IL-36β and IL-36γ)¹*